SCHEMBL4833255

SCHEMBL4833255

Brc1c[c]ccc1OCc1ccccc1OCc1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
HTR1A P08908 1/20 0.43
DRD2 P14416 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
NPY1R P25929 1/20 0.41
HTT P42858 1/20 0.41
NPY2R P49146 1/20 0.41
KMT2A Q03164 1/20 0.41
RAB9A P51151 2/20 0.40
CCR5 P51681 2/20 0.39
SLC2A1 P11166 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
USP28 Q96RU2 1/20 0.38
USP25 Q9UHP3 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11513558 0.83 RAB9A (0.46) HTR1ADRD2SMN1; SMN2RAB9A
SCHEMBL4833245 0.78 ABCB1 (0.44) ABCB1ABCG2HTR1ADRD2SMN1; SMN2
SCHEMBL5475735 0.73 MAOB (0.51) LMNAKMT2A
SCHEMBL183414 0.73 MAPT (0.48) HTR1ADRD2SMN1; SMN2LMNARAB9A
SCHEMBL9232295 0.72 TDP1 (0.44) HTR1ADRD2SMN1; SMN2LMNARAB9A
SCHEMBL7243289 0.69 HTR1A (0.47) ABCB1HTR1ADRD2KDM4ELMNA
SCHEMBL27684708 0.69 HTR1A (0.47) ABCB1HTR1ADRD2SMN1; SMN2KDM4E
SCHEMBL28317762 0.69 TSHR (0.48) ABCB1HTR1ADRD2SMN1; SMN2KDM4E
SCHEMBL1995693 0.69 RAB9A (0.56) SMN1; SMN2KDM4ELMNAKMT2ARAB9A
SCHEMBL3236287 0.68 SLC2A1 (0.52) KDM4EKMT2ARAB9ASLC2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US claimed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US claimed
WO-2005014534-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO claimed
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US disclosed
WO-2005014534-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO ABCB1 351/4885ABCG2 113/4885HTR1A 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.